|
Medical Malpractice and Pharmaceutical
There have been rapid advances in pharmaceutical efficacy, combined with increasingly sophisticated and complicated medical procedures which mean that understanding and underwriting such business is time consuming and involved.
The level of research required and the need to keep abreast of problems and progress in these fields is essential. Industry developments, happening at an ever-increasing rate, can mean huge changes in exposure for different segments of the profession.
QBE are able to meet these challenges through detailed and careful underwriting criteria.
The maximum line size is USD10,000,000 for medical malpractice and USD30,000,000 for pharmaceutical liability.
The team currently has a gross written premium in excess of £60m.
Scope of cover
- Medical Malpractice
- Pharmaceutical public and products liability
- Clinical trials
Preferred business
The portfolio encompasses medical malpractice, clinical trials and clinical research establishments, complementary medicine, day care (surgical and non-surgical), health and beauty, hospitals, medical practitioners, regional health authorities, pharmaceutical and medical product manufacturers and distributors, API/contract manufacturers and importers of pharmaceuticals.
Pharmaceutical manufacturers covers both ethical and generic drug producing companies.
The client base is worldwide but with restrictions applicable on US domiciled manufacturing exposures
Policy Details
Cover is provided on either a primary or excess of loss or on direct or facultative reinsurance basis. Standard or bespoke wordings are used but strictly on a claims-made basis. Losses occurring policies, in respect of public liability and pollution liability, can also be considered.
The maximum line size is USD10,000,000 for medical malpractice and USD30,000,000 for pharmaceutical liability.
|
